Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04266392 · ClinicalTrials.gov registry record · Early Phase 1
Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand
A Early Phase 1 study, sponsored by Stony Brook University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
NCT04266392 is a Early Phase 1 study that has completed, run by Stony Brook University. The registered enrollment target is 20 participants.
The verdict
NCT04266392, a Early Phase 1 study, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Eligible patients have prostate cancer that was treated with surgery or radiation therapy for localized disease and there is evidence of biochemical recurrence and/or metastases on conventional imaging.The objective of this study is to assess the performance in detection of prostate cancer of a new positron emission tomography (PET) radiotracer for prostate cancer (\[18F\]-DCFPyl) combined with magnetic resonance imaging (MRI). Results of tracer uptake and MRI image features as whole body PET/MRI and dedicated pelvic/prostate PET/MRI, alone and together, will be correlated and compared to detection of lesions on conventional imaging modalities. Additionally, if the patient undergoes a biopsy as standard of care, image features will correlate directly with histopathological findings.Validation of this radiotracer can potentially lead to its use as a standard of care for future imaging and improve diagnosis and treatment guidance.This drug is not approved by the Food and Drug Administration (FDA) and is therefore considered experimental.There will be 20 subjects enrolled in this study; all of these patients will be enrolled at Stony Brook University Medical Center.
Interventions
- DRUG [18F]-DCFPyl Ligand
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2019-12-16 |
| Est. Completion | 2021-10-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04266392
The ClinicalTrials.gov registry entry for NCT04266392 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stony Brook University, which has 127 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [18F]-DCFPyl Ligand is the first listed.
NCT04266392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04266392 about?
NCT04266392 is a clinical study titled "Molecular Imaging of Prostate Cancer Using Radiofluorinated PSMA Ligand". Eligible patients have prostate cancer that was treated with surgery or radiation therapy for localized disease and there is evidence of biochemical recurrence and/or metastases on conventional imaging.The objective of this study is to assess the performance in detection of prostate cancer of a new ...
What is the current status of trial NCT04266392?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2019-12-16. Estimated completion is 2021-10-15.
What interventions are being tested in trial NCT04266392?
The interventions under investigation include: [18F]-DCFPyl Ligand (DRUG).
Who is sponsoring clinical trial NCT04266392?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.